ArticleCurrent microbiology2025
Integrated in Vitro, in Vivo, Molecular Docking, and ADMET in Silico Assessment of β-Caryophyllene as a NorA Efflux Pump inhibitor in Resistant Staphylococcus Aureus (MRSA).
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Composition and Antibacterial Activity Against Food-Borne Pathogens of Six Essential Oils from Plants in Northeastern Peru.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efflux pumps are one of the main mechanisms used by bacteria for antimicrobial resistance. These protein structures are capable of extruding antibiotics and reducing their intracellular concentrations to non-toxic levels for the bacterial cell. Thus, due to the absence of clinically approved products capable of acting as efflux pump inhibitors (EPIs), this study aimed to investigate the potential of the sesquiterpene β-caryophyllene to act as an EPI of the NorA pump present in Staphylococcus aureus strains, through in vitro, in vivo, and in silico approaches. For this purpose, in in vitro assays, the terpene was combined at a sub-inhibitory concentration with norfloxacin or ethidium bromide. In in vivo tests using the Zebrafish model, the animals were intramuscularly infected and orally treated with the terpene combined with norfloxacin. Additionally, molecular docking was performed with the NorA protein to predict ligand interactions, as well as ADME/Tox predictions. Overall, the molecular docking assays revealed that β-caryophyllene shows good affinity for the active site of the NorA protein, promoting hydrophobic interactions and hydrogen bonds with key residues such as PHE86. This was supported by in vitro assays, in which the compound was able to reduce the minimum inhibitory concentration (MIC) of norfloxacin when combined with it. This activity was also corroborated in vivo, where the association between β-caryophyllene and norfloxacin significantly reduced the number of colony-forming units (CFUs) in infected muscle tissues. ADMET property predictions demonstrated good intestinal absorption, absence of interaction with cytochrome P450 enzymes, and low hepatic toxicity; however, potential immunotoxicity and adverse effects on the blood-brain barrier (BBB) were observed. Therefore, β-caryophyllene emerged as a promising candidate for inhibiting the NorA efflux pump.
Indexed as
Identifiers
41286366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.